HC Wainwright reiterates Buy on MetaVia, $20 target

1 min read Updated on 10 Jul 2026, 05:15 PM

Reviewed by

Shraddha JScanX News Team

AI Summary

HC Wainwright & Co. analyst Andrew S. Fein reiterated a Buy rating on MetaVia and maintained a $20 price target. MetaVia recently announced that all enrolled active patients in Part 3 of its Phase 1 clinical trial for DA-1726 have completed dose titration and are receiving highest target doses of 48 mg and 64 mg. The company remains on track to report topline data in the fourth quarter of 2026.

*this image is generated using AI for illustrative purposes only.

HC Wainwright & Co. analyst Andrew S. Fein has reiterated a Buy rating on MetaVia (NASDAQ: MTVA) and maintained a $20 price target. This endorsement follows the company's recent announcement that all enrolled active patients in Part 3 of its Phase 1 clinical trial evaluating DA-1726 for obesity have successfully completed dose titration and are now receiving their highest target doses.

MetaVia Inc. reported that patients in both study cohorts are receiving the highest target doses, keeping the company on track to report topline data in the fourth quarter of 2026. DA-1726 is a novel oxyntomodulin (OXM) analog targeting both GLP-1 (GLP1R) and glucagon (GCGR) receptors. Part 3 of the Phase 1 program consists of two 16-week titration cohorts designed to evaluate one-step and two-step dose-escalation strategies to safely achieve higher target doses and further optimize tolerability.

In Part 3A, patients titrated from 16 mg to 48 mg, while in Part 3B, patients titrated from 16 mg to 32 mg and subsequently to 64 mg. The successful completion of dose titration in these cohorts marks a significant step in the clinical development of the potential obesity treatment.